





American  
Heart  
Association.

# **Amyloid-Related Imaging Abnormalities (ARIA) Summit: Cardiovascular and Stroke Considerations for $\beta$ -Amyloid Immunotherapy in Alzheimer Disease**

May 11–12, 2026

Valkenburg, The Netherlands





## Overview

The American Heart Association welcomes you to the Amyloid-Related Imaging Abnormalities (ARIA) Summit: Cardiovascular and Stroke Considerations for  $\beta$ -Amyloid Immunotherapy in Alzheimer Disease. This Summit has convened invited experts from diverse fields—including neurology, cardiology, emergency medicine, nursing, neuroradiology and more—to share insights on ARIA and explore considerations for issues related to the use of amyloid plaque-lowering monoclonal antibodies and their side effects.

Through a series of plenary presentations and focused breakout sessions, participants will explore clinical and systems of care considerations for implementing  $\beta$ -amyloid therapies in patients with cardiovascular or stroke risk. These insights will inform the development of an ARIA Summit Special Report.

## Agenda

### Day One: Monday, May 11, 2026

- 12:30 Registration & Lunch**
- 14:00 Welcoming & Opening Remarks**  
Mitchell S.V. Elkind, MD, MS, Chief Science Officer for Brain Health and Stroke, American Heart Association, United States
- 14:10 Patient Perspective Interview**
- 14:30 Plenary Session 1 – Pathophysiology of ARIA**  
Delphine Boche, PhD, University of Southampton, United Kingdom
- 15:00 Plenary Session 2 – Clinical Overview of ARIA**  
Tara Carlisle, MD, PhD, University of Colorado Anschutz Medical Campus, United States
- 15:30 Break**

- 15:45 Plenary Session 3 – Vascular Considerations for Patient Selection and Acute Patient Management**  
Mariel Kozberg, MD, PhD, Massachusetts General Hospital and Harvard Medical School, United States
- 16:15 Plenary Session 4 – Developing Systems of Care: Perspectives on the Patient Journey**  
*Presentation*  
Kyra O’Brien, MD, MSHP, Penn Medicine, United States  
*Panel Discussion*  
Karl-Olof Lövblad, MD, Geneva University Hospital, Switzerland  
Kyra O’Brien, MD, MSHP, Penn Medicine, United States  
Gerhard Ransmayr, MD, Johannes Kepler University Linz, Austria  
Nikolaos Scarmeas, MD, PhD, Medical School of the National and Kapodistrian University of Athens, Greece  
*Moderator*  
Federica Agosta, MD, PhD, Vita-Salute San Raffaele University, Italy

- 17:00 Wrap Up of Day 1**
- 18:00 Four-Course Dinner with Wine Pairing**

### Day Two: Tuesday, May 12, 2026

- 8:00 Breakfast**
- 8:30 Review Goals and Deliverables for Breakout Sessions**  
Mitchell S.V. Elkind, MD, MS
- 8:45 Breakout Session 1: Work Groups A–C**
- 10:00 Breakout Session 2: Work Groups D–F**
- 11:15 Break**
- 11:30 Breakout Session Recaps**
- 12:45 Closing Remarks & Next Steps**
- 13:00 Adjourn**
- 13:00 Lunch available**

## Co-Chairs



### **Federica Agosta, MD, PhD**

Dr. Agosta is an Associate Professor of Neurology at Vita-Salute San Raffaele University, Group Leader of the Neuroimaging of Neurodegenerative Diseases Unit at the Institute of Experimental Neurology, Division of Neuroscience; Director of the Strategic Program on Neurodegenerative Diseases and Alzheimer's Disease; and member of the Center for Alzheimer's disease

and related disorders (CARD), Ospedale San Raffaele, Milano, where she conducts clinical activity and research in patients with neurodegenerative conditions. She has a broad background in clinical neurology and neuroimaging, with specific training and expertise in MRI in neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia, primary progressive aphasia and amyotrophic lateral sclerosis.



### **Tara Carlisle, MD, PhD**

Dr. Carlisle is the Medical Director of the Advanced Therapy in Neurodegenerative Disorders (ATND) Clinic that she created. She received training in the Medical Scientist Training Program at the University of Colorado (CU) Anschutz Medical Campus (AMC) in the Neuroscience PhD program, completed an Internal Medicine internship with CU School of Medicine (SOM), Neurology

Residency with Mass General-Brigham/Harvard (Partners) Neurology, and Behavioral Neurology & Neuropsychiatry Fellowship with CU SOM. Dr. Carlisle's research and clinical interests are in cognitive reserve and resiliency, sex differences in neurodegenerative disorders, and personalized approaches to prevent and/or slow cognitive decline.



### **Fergus Doubal, MBChB, PhD**

Dr. Doubal is an Honorary Reader at the University of Edinburgh and a Consultant Stroke Physician and Geriatrician at the Royal Infirmary of Edinburgh, United Kingdom. He is the NHS Lothian Managed Clinical Network clinical lead for stroke and chairs the European Stroke Organisation Dementia sub-committee. He has authored clinical guidelines for the American Heart

Association and European Stroke Organisation and chaired the British and Irish Association of Stroke Physicians Clinical Standards Committee. His research focuses on cerebral small vessel disease.



### **Mariel Kozberg, MD, PhD**

Dr. Kozberg is an Assistant Professor of Neurology at Harvard Medical School and a vascular neurologist at Massachusetts General Hospital (MGH). Her research utilizes a range of techniques from in vivo two-photon microscopy of mouse models of cerebral amyloid angiopathy (CAA) to quantitative histopathology of human tissue with the goal of understanding the mechanisms

of blood vessel dysfunction and rupture in CAA. Clinically, Mariel has appointments within both the Stroke and Memory Divisions at Mass General Brigham. She attends on the inpatient stroke and acute stroke services at MGH. She is also an advisor on multiple workgroups within the Mass General Brigham Alzheimer's Therapeutics Program. Her outpatient practice is centered on providing care to patients with CAA and other small vessel diseases.

## Speakers



### **Delphine Boche, PhD**

Dr. Boche is a Professor of Neuroimmunopathology at the Faculty of Medicine, University of Southampton, UK. Her research focuses on understanding neuroinflammation and its consequences in patients affected by neurological diseases. She obtained her PhD in 1997 at the Pasteur Institute in Paris, France, and joined the University of Southampton in 1999 to study the neuroinflammation in acute and chronic neurodegenerative diseases. In 2004, she moved to the Faculty of Medicine to investigate the pathophysiology of Alzheimer's disease in patients immunized against A $\beta$ . Since, she has developed protocols to immunophenotype immune cells in human brain using markers relating to a specific function, allowing the investigation of the role of these cells in different neurological conditions.



### **Kyra O'Brien, MD, MSHP**

Dr. O'Brien is an Assistant Professor of Neurology at the University of Pennsylvania and serves as Medical Director of the Penn Medicine Guiding an Improved Dementia Experience (GUIDE) program. She treats patients with Alzheimer's disease and related dementias at the Penn Memory Center, and she conducts health services research examining care pathways to improve diagnosis and treatment for individuals with cognitive impairment.



### **Mitchell S.V. Elkind, MD, MS\***

Dr. Elkind is the American Heart Association's Chief Science Officer for Brain Health and Stroke and serves as the senior staff science leader for all Association initiatives related to stroke, brain health and new integrated efforts, including cardio-renal-metabolic health. His research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke and vascular causes of cognitive aging.

\*Also a Planning Committee member



### **Karl-Olof Lövblad, MD\***

Professor Lövblad is the Head of Diagnostic and Interventional Neuroradiology in the Diagnostic Department at Geneva University Hospitals and Professor in the Department of Radiology and Medical Informatics. He has served as Associate Editor of the Journal of Neuroradiology since 2013 and sits on the editorial boards of several journals including Neuroradiology and European Neurology. Since 2016, he has chaired the Verein der leitenden Spitalärzte der Schweiz (VLSS), the association of Swiss chief hospital physicians, and represents this organization at the Medical Chamber and Delegates' Assembly of the FMH. He has served as the National Delegate for Switzerland to the European Society of Neuroradiology (ESNR) since 2011 and was a member of this society's scientific committee from 1999 to 2002.



### **Gerhard Ransmayr, MD**

Dr. Ransmayr is an Associate Professor and Lecturer of the Medical Faculty at the Johannes Kepler University in Linz, Austria, specializing in neurology, psychiatry, and geriatric medicine. He formerly served as the Head of the Department of Neurology II, Kepler University Hospital in Linz, President of the Austrian Parkinson Society, a member of the extended managing board of the Austrian Parkinson Society, and a member of the Austrian Alzheimer Society. He currently serves as a member of the Austrian Neurological Society, the International Parkinson and Movement Disorder Society, and the American Academy of Neurology and is a reviewer for multiple neurological journals.




### **Nikolaos Scarmeas, MD, PhD\***

Dr. Scarmeas is a Professor of Neurology at the Medical School of the National and Kapodistrian University of Athens, maintaining an Academic affiliation with Columbia University in New York. His research interests include cognitive reserve (i.e. how higher IQ, education, more demanding occupational attainments, or more engagement in cognitive-social-physical leisure – lifestyle activities can help elderly cope better with the damage caused to their brains by Alzheimer's disease and aging and therefore reduce their risk for

dementia and slow down their rates of cognitive and functional decline). In addition, he has extensively investigated the contribution of diet (in particular composite dietary patterns such as a Mediterranean-type diet and others) in relation to dementias, Alzheimer's disease, cognitive and other aspects of aging.

## Additional Planning Committee Members

A multidisciplinary planning committee of clinicians, researchers and organization leaders has been convened to inform the event agenda and support the development of the Summit Special Report.



### **Diana Aguiar de Sousa, MD, PhD**

Dr. Aguiar de Sousa is a Portuguese neurologist working at Lisbon Central University Hospital – ULS São José. She is also an Assistant Professor at Faculdade de Medicina, Universidade de Lisboa, and investigator at the Gulbenkian Institute for Molecular Medicine. She serves as Co-Chair of the Guideline Board at the European

Stroke Organisation (ESO) and a member of the Steering Committee for the Implementation of the Stroke Action Plan for Europe. She is also a member of the Clinical Research Subcommittee of the American Academy of Neurology (AAN).



### **Sheena Aurora, MD**

Dr. Aurora serves as the Vice President, Medical Affairs at the Alzheimer's Association, where she translates research into clinical practice and gathers feedback from clinical practice/health systems and individuals impacted by dementia to more effectively implement risk reduction strategies, diagnosis, treatments, and

care models. She works to ensure the Association is developing the most robust tools and resources for health systems, clinicians, and payers to ensure they are offering the most appropriate and safest access to patients.



### **Alessandro Biffi, MD**

Dr. Biffi is the Associate Vice President, Lilly Neuroscience, of Eli Lilly and Company. He graduated from the University of Milan Bicocca Medical School in Italy and pursued clinical residency and fellowship training in neurology at Harvard Medical School. He established a clinical research program at Massachusetts General

Hospital and Harvard Medical School investigating the intersection of neurodegenerative, cerebrovascular and psychiatric disorders. He has made high-profile contributions in the fields of neurogenomics, neuropsychiatry, vascular and cognitive neurology.



### **Noa Bregman, MD**

Dr. Bregman is a neurologist and Director of the Cognitive Neurology Unit at Tel Aviv Sourasky Medical Center (TASMC), Israel, and a Senior Lecturer at the Grey Faculty of Medicine and Sagol School of Neuroscience at Tel Aviv University. She specializes in cognitive neurology, with a focus on Alzheimer's disease (AD),

Dementia with Lewy Bodies (DLB), and prion diseases. She leads a multidisciplinary clinical and research program dedicated to early diagnosis and advanced therapies for neurodegenerative diseases. She established the Center for Advanced Treatments in Alzheimer's Disease at TASMC, one of the first centers outside of the United States to implement amyloid-targeting therapies, including lecanemab and donanemab, in routine clinical practice.

*We would like to thank  
the **European Stroke Organisation** and  
the **Alzheimer's Association**  
for their contributions to this Summit.*





American  
Heart  
Association.

*Lilly*

A MEDICINE COMPANY

Lilly is a supporter of the American Heart  
Association's ARIA Summit.